TissueLabs will distribute MatriWell™ free of charge to all the researchers developing studies on the new coronavirus (SARS-Cov-2)

 

The coronavirus pandemic has forced several sectors of society to interrupt their activities, in many cases indefinitely. Although the worse has passed, we must be prepared for new spreading waves of the disease. Despite studies on the efficacy of existing drugs, there is and will be an urgent need for the scientific community to rapidly expand its knowledge about the new coronavirus (SARS-CoV-2) and potential therapeutic targets. 

​

The current platforms available for in vitro investigation of the coronavirus in the pulmonary epithelium are not representative of the tissue found in the human lung. In general, two-dimensional cultures, traditionally used in biomedical research, subject cells to a microenvironment that is very distinct from that found in the body. Ultimately, this leads to hundreds of new compounds being subjected to pre-clinical and clinical tests, with a low success rate, wasting resources that could be applied to the development of compounds with a higher chance of success. 

​

With this worrying scenario in mind, TissueLabs team

developed a platform for  the in vitro study of the SARS-CoV-2

in the lung epithelium, which is affected during the disease process,

the MatriWell™. The platform contains the extracellular matrix

from the lungs, just as cells would find in patients' organs.

The researcher is free to personalize the type and origin

of the cells to be used with the platform. It means, for instance,

that it would be possible to use cells from patients with other

comorbidities, such as asthma and COPD,

to create personalized 3D tissues. 

​

MatriWell™ will be distributed free of charge to researchers developing studies on the new coronavirus. To request it, researchers must complete the application form below.